Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe, Diagnocure Amend Prostate Cancer Test Deal

NEW YORK (GenomeWeb News) – Gen-Probe and DiagnoCure said this week that they have amended their 2003 license agreement regarding development and commercialization of a molecular diagnostic test for prostate cancer.

The amended deal establishes new Food and Drug Administration milestones and key distribution arrangements, the partners said in a joint statement.

San Diego-based Gen-Probe can fulfill the milestone for an FDA submission with its current end-point TMA assay or its investigational real-time TMA assay, they said. As part of the amendment, Gen-Probe will make annual payments of $500,000 to Diagnocure until specific milestones are met. Half of the amounts paid to DiagnoCure will be applied against future royalties payable to the Quebec-based firm.

As part of the deal, Gen-Probe will acquire 4.9 million shares of newly issued DiagnoCure convertible preferred stock for $5.0 million, representing a premium of 19.8 percent over the average market price of DiagnoCure's common shares during the 20 trading days from April 28. The convertible preferred shares are non-voting, and may be exchanged for common shares on a one-for-one basis, the firm's said.

Gen-Probe also said that it plans to initiate a pivotal clinical trial of the PCA3-based prostate cancer test during the third quarter of this year for potential regulatory clearance by FDA.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.